SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.
Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...
The Pharma Letter23h
Sage rejects Biogen’s unsolicited bid, but open to other offers
Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...
Hosted on MSN19h
Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
marketinference2h
Sage Therapeutics Rejects Biogen's Acquisition Proposal
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...
BioSpace2h
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
EconoTimes23h
FxWirePro- Major Crypto levels and bias summary
Major Crypto levels and ...
Yahoo Finance18h
Hard to Treat Diseases Inc. (HTDS)
President Trump wants to eliminate the tax credit for electric vehicles buyers, but that won't stop General Motors (GM) from making them. In an interview with Yahoo Finance Executive Editor Brian ...